Marta Chesi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4322763/publications.pdf

Version: 2024-02-01

60	6,221	257429 24	206102 48
papers	citations	h-index	g-index

62	62	62	10907
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma. Oncotarget, 2022, 13, 490-504.	1.8	2
2	Expression of Nras Q61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood, 2021, 137, 61-74.	1.4	21
3	Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy. Blood Cancer Discovery, 2021, 2, 354-369.	5.0	37
4	Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. Nature Communications, 2021, 12, 6322.	12.8	12
5	Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma. Blood, 2021, 138, 1593-1593.	1.4	0
6	Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability. Blood, 2021, 138, 2687-2687.	1.4	0
7	Selective Cell State in the Clonally Expanded T-Cell Compartment of Vβ*MYC Mice Responding to Treatment with Checkpoint Inhibitors. Blood, 2021, 138, 1581-1581.	1.4	0
8	Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. Leukemia, 2020, 34, 245-256.	7.2	38
9	MYC dysregulation in the progression of multiple myeloma. Leukemia, 2020, 34, 322-326.	7.2	108
10	Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression. Blood Cancer Discovery, 2020, 1, 68-81.	5.0	24
11	Identification of PIKfyve kinase as a target in multiple myeloma. Haematologica, 2020, 105, 1641-1649.	3.5	25
12	Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition. Blood, 2020, 136, 1-2.	1.4	0
13	Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression. Blood Cancer Discovery, 2020, 1, 68-81.	5.0	0
14	Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. Blood Advances, 2019, 3, 797-812.	5.2	22
15	Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia, 2019, 33, 1011-1022.	7.2	37
16	Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. JCI Insight, 2019, 4, .	5.0	20
17	MiR-16 regulates crosstalk in NF-ÎºB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight, 2019, 4, .	5.0	33
18	Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide. Blood, 2019, 134, 4410-4410.	1.4	0

#	Article	IF	Citations
19	Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma. Blood, 2019, 134, 3059-3059.	1.4	1
20	Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. Cancer Cell, 2018, 33, 634-648.e5.	16.8	163
21	Importin-Î² and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells. Annals of Diagnostic Pathology, 2018, 32, 28-34.	1.3	2
22	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nature Communications, 2018, 9, 4832.	12.8	144
23	Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight, 2018, 3, .	5.0	43
24	Blocking IFNAR1 inhibits multiple myelomaâ€“driven Treg expansion and immunosuppression. Journal of Clinical Investigation, 2018, 128, 2487-2499.	8.2	80
25	Bone marrow transplantation generates T cellâ€“dependent control of myeloma in mice. Journal of Clinical Investigation, 2018, 129, 106-121.	8.2	49
26	A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma. Blood, 2018, 132, 56-56.	1.4	2
27	Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure. Blood, 2018, 132, 2031-2031.	1.4	0
28	Reconstructing the Clonal and Mutational Architecture of Myeloma through Avian Leukosis Virus (ALV)-Mediated Genome Editing. Blood, 2018, 132, 4480-4480.	1.4	0
29	Mice Expressing MYC and NrasQ61R in Germinal Center B Cells Develop Highly Aggressive Multiple Myeloma. Blood, 2018, 132, 1006-1006.	1.4	3
30	Antibodies Create Killer Bonds in Myeloma. Cancer Cell, 2017, 31, 305-307.	16.8	2
31	Multiple myeloma cellsâ€™ capacity to decompose H2O2 determines lenalidomide sensitivity. Blood, 2017, 129, 991-1007.	1.4	33
32	Promiscuous mechanisms underlie the antitumor effects of thalidomide analogs. Nature Medicine, 2016, 22, 706-707.	30.7	5
33	Phase II trial of nabâ€paclitaxel in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 2016, 91, E504-E505.	4.1	6
34	IAP antagonists induce anti-tumor immunity in multiple myeloma. Nature Medicine, 2016, 22, 1411-1420.	30.7	133
35	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. OncoImmunology, 2015, 4, e1008850.	4.6	27
36	Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunology Research, 2015, 3, 881-890.	3.4	24

#	Article	IF	Citations
37	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. Journal of Clinical Investigation, 2015, 125, 2077-2089.	8.2	111
38	Transcriptional repression by the HDAC4â€“RelBâ€“p52 complex regulates multiple myeloma survival and growth. Nature Communications, 2015, 6, 8428.	12.8	53
39	UCHL1is a biomarker of aggressive multiple myeloma required for disease progression. Oncotarget, 2015, 6, 40704-40718.	1.8	39
40	TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood, 2014, 123, 3305-3315.	1.4	89
41	Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia, 2014, 28, 1725-1735.	7.2	221
42	Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. Leukemia Research, 2014, 38, 948-954.	0.8	14
43	Inhibition Of RNA Polymerase I Transcription By CX-5461 As a Therapeutic Strategy For The Cancer-Specific Activation Of p53 In Highly Refractory Haematological Malignancies. Blood, 2013, 122, 3941-3941.	1.4	4
44	Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood, 2012, 120, 376-385.	1.4	174
45	PARP Inhibition (OLAPARIB) Enhance Melphalan and Nutlin-3a Sensitivity in TP53 Positive Multiple Myeloma. Blood, 2012, 120, 1846-1846.	1.4	1
46	Promiscuous Cryptic Rearrangements of the MYC Locus Cis-Dysregulate MYC Expression and Are Present in the Majority of Patients with Hyperdiploid Myeloma. Blood, 2012, 120, 724-724.	1.4	1
47	Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276. Blood, 2012, 120, 573-573.	1.4	1
48	Many Multiple Myelomas: Making More of the Molecular Mayhem. Hematology American Society of Hematology Education Program, 2011, 2011, 344-353.	2.5	46
49	BET Bromodomain Inhibition asÂa Therapeutic Strategy to Target c-Myc. Cell, 2011, 146, 904-917.	28.9	2,432
50	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	1.4	0
51	Examining Measures of Proliferation for Use in Risk Stratification of Myeloma. Blood, 2011, 118, 5093-5093.	1.4	0
52	The Murine Vk*MYC Myeloma Shares Defining Genetic Lesions with Human Multiple Myeloma.. Blood, 2009, 114, 1808-1808.	1.4	2
53	AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. Cancer Cell, 2008, 13, 167-180.	16.8	322
54	Promiscuous Mutations Activate the Noncanonical NF-ÎºB Pathway in Multiple Myeloma. Cancer Cell, 2007, 12, 131-144.	16.8	941

#	Article	IF	Citations
55	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. Blood, 2007, 110, 241-241.	1.4	1
56	A Novel Transgenic Mouse Model of Multiple Myeloma Reliably Predicts Drug Response.. Blood, 2006, 108, 241-241.	1.4	1
57	High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.. Blood, 2006, 108, 3407-3407.	1.4	0
58	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. Blood, 2005, 106, 3381-3381.	1.4	0
59	The Multiple Myeloma SET Domain (MMSET) Protein Is a Histone H3 and H4 Methyltransferase with Properties of a Transcriptional Co-Repressor.. Blood, 2005, 106, 358-358.	1.4	0
60	Genetics and Cytogenetics of Multiple Myeloma. Cancer Research, 2004, 64, 1546-1558.	0.9	642